Kiniksa Pharmaceuticals International, plc (KNSA)
| Market Cap | 4.13B |
| Revenue (ttm) | 677.56M |
| Net Income (ttm) | 59.01M |
| Shares Out | 76.85M |
| EPS (ttm) | 0.75 |
| PE Ratio | 58.15 |
| Forward PE | 34.24 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,321,635 |
| Open | 47.20 |
| Previous Close | 43.61 |
| Day's Range | 45.01 - 53.53 |
| 52-Week Range | 21.25 - 53.71 |
| Beta | 0.06 |
| Analysts | Strong Buy |
| Price Target | 58.43 (+8.79%) |
| Earnings Date | Apr 28, 2026 |
About KNSA
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericard... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for KNSA stock is "Strong Buy." The 12-month stock price target is $58.43, which is an increase of 8.79% from the latest price.
News
Kiniksa Pharmaceuticals International, Earnings Call Transcript: Q1 2026
Q1 2026 saw robust ARCALYST revenue growth, record new prescribers, and raised full-year guidance to $930M–$945M. Pipeline programs advanced, with KPL-387 phase II data expected in H2 and phase III to start by year-end. Cash position remains strong.
Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution
– ARCALYST ® (rilonacept) Q1 2026 net product revenue of $214.3 million, representing 56% year-over-year growth – – ARCALYST 2026 expected net product revenue increased to $930 - $945 million – – KPL-...
Kiniksa Pharmaceuticals to Report First Quarter 2026 Financial Results on April 28, 2026
LONDON, April 23, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, April 28, 2026 at ...
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains This Month
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Kiniksa Pharmaceuticals Launches Targeted Direct-To-Consumer TV Campaign for ARCALYST® (rilonacept) in Recurrent Pericarditis
– Educational campaign to raise awareness of recurrent pericarditis and to empower patients to discuss ARCALYST with their healthcare provider – – Media accompanying this announcement is available by ...
Kiniksa Pharmaceuticals International, Transcript: TD Cowen 46th Annual Health Care Conference
Strong revenue growth in 2025 was driven by increased patient numbers, prescriber engagement, and longer therapy duration, with significant market opportunity remaining. Pipeline progress includes upcoming Phase II data for KPL-387 and ongoing development of KPL-1161, supported by robust cash flow and a disciplined approach to expansion.
Kiniksa Pharmaceuticals to Present at TD Cowen 46th Annual Health Care Conference
LONDON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the TD Cowen 46th Annual Heal...
Kiniksa Pharmaceuticals International, Earnings Call Transcript: Q4 2025
ARCALYST revenue surged 62% year-over-year to $677.6 million in 2025, with net income turning positive and strong cash generation. Pipeline progress continues with KPL-387 and KPL-1161, and 2026 revenue guidance is set at $900–$920 million.
Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Portfolio Execution
– ARCALYST ® (rilonacept) Q4 2025 and full year 2025 net product revenue of $202.1 million and $677.6 million, respectively – – ARCALYST 2026 net product revenue expected to be $900 - $920 million – –...
Kiniksa Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
LONDON, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, February 24, 2026 a...
Kiniksa Pharmaceuticals International, Transcript: 44th Annual J.P. Morgan Healthcare Conference
Significant revenue growth and market expansion were highlighted, with ARCALYST now established as the second-line standard of care for recurrent pericarditis. Pipeline progress includes KPL-387 in phase 2/3 trials and KPL-1161 entering the clinic by year-end, supporting a robust outlook.
Kiniksa Pharmaceuticals Provides Corporate Update
– ARCALYST ® (rilonacept) 2025 net product revenue of $677.5 million (unaudited), representing ~62% year-over-year growth – – ARCALYST 2026 net product revenue expected to be $900 - $920 million – – K...
Kiniksa Pharmaceuticals to Present at 44th Annual J.P. Morgan Healthcare Conference
LONDON, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that it will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday,...
Kiniksa Pharmaceuticals International, Transcript: Jefferies London Healthcare Conference 2025
ARCALYST continues robust growth with increased early adoption and strong 2025 revenue guidance. KPL-387, a monthly IL-1 inhibitor, advances in phase 2/3 trials, with high physician and patient interest and potential launch by 2028–2029.
Kiniksa Pharmaceuticals to Present at Jefferies Global Healthcare Conference in London
LONDON, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will present at the Jefferies Global Healthcare Conference in London...
Kiniksa Pharmaceuticals International, Earnings Call Transcript: Q3 2025
Q3 2025 saw ARCALYST revenue surge 61% year-over-year to $180.9 million, driving a net income of $18.4 million and prompting a raised full-year sales guidance to $670–$675 million. Market adoption and prescriber growth remain strong, with KPL-387 advancing in development.
Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution
– ARCALYST ® (rilonacept) Q3 2025 net product revenue of $180.9 million, representing 61% year-over-year growth – – ARCALYST 2025 expected net product revenue raised to $670 - $675 million – – KPL-387...
Kiniksa Pharmaceuticals to Report Third Quarter 2025 Financial Results on October 28, 2025
LONDON, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, October 28, 2025 at...
Kiniksa Pharmaceuticals Announces U.S. Orphan Drug Designation for KPL-387 for the Treatment of Pericarditis
LONDON, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases w...
Kiniksa Pharmaceuticals International, Transcript: Wells Fargo 20th Annual Healthcare Conference 2025
ARCALYST continues strong revenue growth with expanded prescriber base and increased patient duration, while new Medicare Part D policies provided a one-time boost. Pipeline programs KPL-387 and 1161 are advancing, with KPL-387 showing high physician and patient interest. Cash flow remains positive as development and commercialization efforts progress.
Kiniksa Pharmaceuticals International, Transcript: Citi's Biopharma Back to School Conference
ARCALYST continues robust growth with strong revenue, expanding prescriber base, and high compliance. New guidelines and real-world data support its use, while KPL-387’s monthly dosing profile is poised to further expand the market. Innovation and global expansion remain strategic priorities.
Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences
LONDON, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in fireside chats at the following investor confere...
Kiniksa Pharmaceuticals International, Earnings Call Transcript: Q2 2025
Q2 net revenue rose 52% year-over-year to $156.8 million, driven by ARCALYST's strong commercial performance and expanded prescriber base. 2025 sales guidance was raised to $625–$640 million, and the KPL-387 Phase 2/3 trial is underway with data expected next year.
Kiniksa Pharmaceuticals Reports Second Quarter 2025 Financial Results and Recent Portfolio Execution
– ARCALYST ® (rilonacept) Q2 2025 net product revenue of $156.8 million, representing 52% year-over-year growth – – ARCALYST 2025 expected net product revenue increased to $625 - $640 million – – KPL-...
Kiniksa Pharmaceuticals to Report Second Quarter 2025 Financial Results on July 29, 2025
LONDON, July 24, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, July 29, 2025 at 8...